MicroPort CardioFlow Medtech Corporation (MP CardioFlow-B) filed its Monthly Return for Equity Issuer for the period ended 30 September 2026, confirming a steady capital structure and limited equity-linked movements during the month.

The company’s authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.000025 each, equivalent to USD 50,000. Issued shares (excluding treasury shares) were stable at 1.27 billion, with no new shares issued, cancelled or held in treasury.

MP CardioFlow reiterated compliance with the Hong Kong Stock Exchange’s 25% minimum public-float requirement.

Option activity was muted but pointed to a slight reduction in potential dilution: • Main Share Option Scheme – Outstanding options fell by 186,436 to 10.33 million following cancellations; no options were exercised, granted or lapsed. • Share Scheme – Outstanding awards declined by 496,543 to 4.61 million due to cancellations.

As at 30 September, up to 10.20 million shares could be issued under the primary option scheme and 1.59 million under the share scheme, with a further 40.73 million reserved for future grants. No proceeds were raised from option exercises during the month.

Overall, the September filing signals status quo in MP CardioFlow’s issued share base, with only marginal option cancellations affecting prospective share issuance capacity.